Teacher Retirement System of Texas decreased its stake in shares of Celgene Co. (NASDAQ:CELG) by 99.4% during the 1st quarter, HoldingsChannel.com reports. The firm owned 2,545 shares of the biopharmaceutical company’s stock after selling 414,720 shares during the quarter. Teacher Retirement System of Texas’ holdings in Celgene were worth $240,000 as of its most recent filing with the SEC.
Several other large investors also recently bought and sold shares of the company. Bruderman Asset Management LLC bought a new position in shares of Celgene during the 4th quarter worth $25,000. Murphy Pohlad Asset Management LLC acquired a new stake in Celgene during the fourth quarter worth about $25,000. Athena Capital Advisors LLC acquired a new stake in Celgene during the fourth quarter worth about $27,000. Investors Research Corp acquired a new stake in Celgene during the first quarter worth about $28,000. Finally, Liberty Wealth Management LLC acquired a new stake in Celgene in the fourth quarter valued at approximately $29,000. Institutional investors own 70.78% of the company’s stock.
Shares of NASDAQ CELG traded down $0.60 during trading on Thursday, hitting $95.76. The stock had a trading volume of 230,168 shares, compared to its average volume of 4,854,612. Celgene Co. has a 12 month low of $58.59 and a 12 month high of $97.07. The company has a debt-to-equity ratio of 2.42, a current ratio of 2.78 and a quick ratio of 2.66. The firm has a market cap of $67.96 billion, a price-to-earnings ratio of 12.58, a PEG ratio of 0.44 and a beta of 1.68.
Several analysts have commented on CELG shares. Mizuho set a $103.00 price objective on Celgene and gave the company a “buy” rating in a research note on Friday, April 5th. Barclays lowered shares of Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 target price for the company. in a research report on Friday, May 3rd. Jefferies Financial Group lowered shares of Celgene from a “buy” rating to a “hold” rating and set a $95.00 target price for the company. in a research report on Friday, February 1st. William Blair downgraded shares of Celgene from an “outperform” rating to a “market perform” rating in a report on Monday, April 1st. Finally, Atlantic Securities downgraded shares of Celgene from an “overweight” rating to a “neutral” rating and set a $94.34 price objective on the stock. in a report on Monday, April 1st. Twenty analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $95.96.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Story: Cryptocurrencies
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.